Want to take quizzes and track your credits?
The urgency of the COVID-19 pandemic led to the scientific triumph of rapid vaccine development against SARS-CoV-2 within less than a year, a period much faster to traditional vaccine development, which spans decades. That impressive speed is credited to a novel approach to vaccine development, with vaccines encoding genetic information in the form of messenger RNA (mRNA) and inducing the body to produce neutralizing antibodies against the SARS-CoV-2 spike protein, the attachment protein for viral entry to cells via the angiotensin-converting enzyme–2 receptor. There are currently 2 mRNA vaccines (Pfizer-BioNTech and Moderna) and 2 adenovirus-based vaccines (Oxford–AstraZeneca and Johnson & Johnson) for which phase 3 placebo-controlled randomized clinical trials (RCTs) published in high-profile journals show an impressive efficacy, although real world effectiveness remains to be further validated in postlicense assessment.1 As very few patients with underlying cancer were enrolled in those studies,2 many unanswered questions remain about the risk-benefit ratio of these new COVID-19 vaccines in patients with cancer.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Dimitrios P. Kontoyiannis, MD, ScD, PhD, Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1460, Houston, TX 77030 (firstname.lastname@example.org).
Published Online: May 13, 2021. doi:10.1001/jamaoncol.2021.1218
Conflict of Interest Disclosures: Dr Kontoyiannis has received research support from Gilead and honoraria from Merck and Gilead. He is a member of the data review committee of Cidara and AbbVie. He acknowledges the Robert C. Hickey Chair endowment. No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.